In the news release, TCBP Announces Shareholder Update Call on March 5th 2024, issued 27-Feb-2024 by TC BioPharm over PR Newswire, we are advised by the company that the first paragraph mention of the shareholder update call time should read "4:30 p.m. ET" rather than "10:00 am" as originally issued inadvertently. The complete, corrected release follows:
EDINBURGH, Scotland, Feb. 27, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that the company will host a shareholder update call on Tuesday, March 5th, 2024, at 4:30 p.m. ET.
Management intends to provide a brief update on the Company's operations, clinical trials as well as insight on the company's 2024 outlook and discuss business development efforts. The Company intends to provide a forum for Q&A after remarks by CEO Bryan Kobel.
Conference Call Information:
Date: | Tuesday, March 05, 2024 |
Time: | 4:30 p.m. Eastern Time |
Live Call: | 1-877-704-4453 (U.S. Toll-Free) or 1-201-389-0920 (International) |
|
About TC BioPharm (Holdings) PLC
TC BioPharm is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer with human efficacy data in acute myeloid leukemia. Gamma-delta T cells are naturally occurring immune cells that embody properties of both the innate and adaptive immune systems and can intrinsically differentiate between healthy and diseased tissue.
TC BioPharm is the leader in developing gamma-delta T cell therapies, and the first company to conduct phase II/pivotal clinical studies in oncology. The Company is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - Phase 2b/3 pivotal trial for OmnImmune® in treatment of acute myeloid leukemia using the Company's proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide.
| Last Trade: | US$0.83 |
| Daily Change: | -0.01 -1.20 |
| Daily Volume: | 47,176 |
| Market Cap: | US$4.110M |
April 04, 2024 February 22, 2024 January 18, 2024 December 18, 2023 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
